Loading...
XJPX
4565
Market cap488mUSD
Dec 05, Last price  
838.00JPY
1D
2.32%
1Q
-15.35%
Jan 2017
-75.08%
IPO
-55.01%
Name

Sosei Group Corp

Chart & Performance

D1W1MN
XJPX:4565 chart
P/E
—
P/S
2.63
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.98%
Rev. gr., 5y
24.28%
Revenues
28.84b
+125.87%
415,501,000739,777,000709,122,000152,911,000919,684,000716,573,000862,412,0001,958,996,0002,069,836,0003,671,309,0008,151,000,00018,901,000,0006,955,000,0003,829,323,7609,726,000,0008,842,000,00017,712,000,00015,569,000,00012,766,000,00028,835,000,000
Net income
-4.84b
L-32.74%
-4,175,711,000-6,239,512,000-6,503,626,000-3,938,646,000-1,769,167,000-1,871,882,000-1,954,389,000-646,856,0001,526,177,000562,522,000-1,547,000,0009,638,000,000-2,654,000,000-7,947,313,6301,432,000,0001,479,000,0001,017,000,000382,000,000-7,193,000,000-4,838,000,000
CFO
-7.72b
L+46.37%
-3,190,478,000-4,181,499,000-3,949,608,000-2,986,214,00032,061,000-89,120,000-286,846,000828,173,000363,279,00092,570,0004,471,000,00012,856,000,000-2,167,000,000-3,995,000,0003,441,000,0004,672,000,0007,095,000,0009,952,000,000-5,273,000,000-7,718,000,000
Dividend
Mar 27, 201510 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of HTL0022562, a calcitonin gene related peptide antagonist, which is in Phase I clinical study; HTL0016878 for neurological diseases; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; and TMP301 and BHV3100 for neurological disorders, which is in clinical trials. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.
URL
https://www.soseiheptares.com/
IPO date
Jul 29, 2004
Employees
211
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT